We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Test Improves Diagnosis of Human Babesiosis

By LabMedica International staff writers
Posted on 18 Jan 2017
Babesia species are tick-borne apicomplexan parasites that infect erythrocytes and several species including B. More...
microti, B. duncani, B. venatorum, B. divergens and B. divergens-like organisms can infect humans.

Babesia infections often are asymptomatic but immunocompromised individuals and even some immunocompetent persons can experience serious, life-threatening manifestations such as splenic rupture, respiratory distress or renal failure. Asymptomatic infected blood donors often are unaware of their infections.

Medical microbiologists and their colleagues at the University of Washington obtained B. microti-containing whole blood samples and negative whole blood samples from de-identified leftover EDTA-anticoagulated clinical samples. The team developed one-step reverse transcription polymerase chain reaction (RT-PCR) for B. microti 18S ribosomal ribonucleic acid (rRNA) as a diagnostic test to take advantage of the biological enrichment of B. microti 18S rRNA as compared to 18S rDNA. This general approach can in future be applied to other Babesia species as well for species specific or pan-Babesia 18S rRNA detection.

Babesia 18S rRNA RT-PCR was performed on an m2000 RealTime System. Nominal densities of B. microti-infected blood samples used for standard curves were measured by counting Giemsa-stained blood smears by microscopy (number of parasites per 2,000 erythrocytes). B. microti-specific primer/probe set was optimized for RT-PCR to generate a highly efficient reaction capable of sub-microscopic B. microti detection.

The assay detected B. microti 18S rRNA in 11 of 11 samples from patients with active or recent B. microti infections. The RT-PCR could detect some samples that may be missed by a PCR-only approach. B. microti 18S rRNA is over 1,000-fold more abundant than its coding genes, making reverse transcription PCR (RT-PCR) much more sensitive than PCR. There was no cross-reactivity against five uninfected blood samples or two high-density Plasmodium falciparum-infected blood samples.

The authors concluded that molecular screening tests for B. microti should be able to detect a single organism in a test volume of ~50–500 μL of whole blood to provide an ultrasensitive limit of detection for use in blood product testing. This limit of detection can likely be achieved using a RT-PCR-based approach and therefore may be useful for screening the blood supply. The study was published on December 5, 2016, in the journal Diagnostic Microbiology and Infectious Disease.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.